APA (7th ed.) Citation

J, D., TL, D., WS, K., JR, C., AJ, M., MO, G., . . . RA, K. (2017). Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Scientific reports, 7(1), 18007. https://doi.org/10.1038/s41598-017-18368-w

Chicago Style (17th ed.) Citation

J, Dey, et al. "Voruciclib, a Clinical Stage Oral CDK9 Inhibitor, Represses MCL-1 and Sensitizes High-risk Diffuse Large B-cell Lymphoma to BCL2 Inhibition." Scientific Reports 7, no. 1 (2017): 18007. https://doi.org/10.1038/s41598-017-18368-w.

MLA (9th ed.) Citation

J, Dey, et al. "Voruciclib, a Clinical Stage Oral CDK9 Inhibitor, Represses MCL-1 and Sensitizes High-risk Diffuse Large B-cell Lymphoma to BCL2 Inhibition." Scientific Reports, vol. 7, no. 1, 2017, p. 18007, https://doi.org/10.1038/s41598-017-18368-w.